Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022
31.3.2022 15:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the details of its presence at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held April 8-13, 2022, both in person in New Orleans, US and virtually. The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery™ and TrueTarget™. Additionally, Biognosys contributed to a poster that will be presented by its collaborator, NeoGenomics.
“The proteome contains a wealth of information about health and disease, and mass spectrometry-based proteomics has great potential in uncovering that information,” commented Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys. “Our AACR data shows how Biognosys has been able to establish mass spectrometry-based proteomics technology to provide detailed and unbiased insights about the proteome. We illustrate how we’ve been able to increase efficiency and scalability at every step of the process. Moreover, we’re showcasing data we’ve generated with our collaborators that demonstrate the practical application of our platforms across all stages of research and drug development, from discovery to clinical settings.”
Biognosys will also be present with a team of scientific experts at booth #885.
Talk Details
-
Abstract 2136: Prediction of small molecule-protein binding events for BRD4 and EGFR inhibitors using HR-LiP, a novel structural proteomics approach
- Presenter: Yuehan Feng, Ph.D.
- Collaborator: Cedilla Therapeutics
- Platform, Technology and Application: TrueTarget, High Resolution Limited Proteolysis Mass Spectrometry (HR-LiP), Drug Target Validation
- Session: Drug Design and Lead Optimization Strategies Toward Novel or Difficult-to-Drug Cancer Targets
- Date and Time: Monday, April 11, 3:20 p.m. - 3:35 p.m. CDT
Poster Presentation Details
-
Abstract 1374: Discovery of MHC class I and class II neoantigens in lung cancer in needle biopsy tissue samples using an optimized high-throughput workflow
- Presenter: Marco Tognetti, Ph.D.
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Immunopeptidome Profiling
- Session: Tumor Antigens, Antigen Presentation, and Tumor Immunity
- Date and Time: Monday, April 11, 9:00 a.m. - 12:30 p.m. CDT
-
Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon targeted therapy treatment using deep phosphoproteomic analysis
- Presenter: Yuehan Feng, Ph.D.
- Collaborator: Crown Bioscience
- Platform, Technology, and Application: TrueDiscovery, Hyper Reaction Monitoring, Phosphoproteome Profiling
- Session: Patient-Derived Xenografts
- Date and Time: Tuesday, April 12, 1:30 p.m. - 5:00 p.m. CDT
-
Abstract 2924: Target identification, selectivity profiling and mechanistic insights of a CDK9 inhibitor using complementary proteomics methods
- Presenter: Yuehan Feng, Ph.D.
- Collaborator: AstraZeneca plc
- Platform, Technology and Application: TrueTarget, Limited Proteolysis Mass Spectrometry (LiP-MS), Drug Target Deconvolution
- Session: Structural and Chemical Biology
- Date and Time: Tuesday, April 12, 9:00 a.m. - 12:30 p.m. CDT
-
Abstract 3923: Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients
- Presenter: Jakob Vowinckel, Ph.D.
- Collaborator: NeoGenomics Laboratories
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
- Session: Proteomics, Signaling Networks, and Biomarker Discovery
- Date and Time: Wednesday, April 13, 9:00 a.m. - 12:30 p.m. CDT
-
Abstract 3920: Precise solid tumor classification through unbiased quantification of proteoforms deep into tissue leakage
- Presenter: Marco Tognetti, Ph.D.
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Biofluid Biomarker Discovery
- Session: Proteomics, Signaling Networks, and Biomarker Discovery
- Date and Time: Wednesday, April 13, 9:00 a.m. - 12:30 p.m. CDT
NeoGenomics Poster Collaboration Details
-
Abstract 1267: Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
- NeoGenomics Presenter: Anna Juncker-Jensen, Ph.D.
- Biognosys co-authors: Nigel Beaton, Ph.D.; Kristina Beeler, Ph.D. Tobias Treiber, Ph.D.; Jakob Vowinckel, Ph.D.
- Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
- Session: Biomarkers Predictive of Therapeutic Benefit 2
- Date and Time: Monday, April 11, 9:00 a.m. - 12:30 p.m. CDT
For the most up to date information and resources about Biognosys’ presence at AACR, visit biognosys.com/accr22.
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
About TrueTarget™
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys.
TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification. The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005060/en/
Contact information
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release
Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 14:00:00 EET | Press release
The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “For generations, Bacardi has had a front-row seat to what’s next in drinks. By combining insights from bar teams, leading venues
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release
Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release
SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release
Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
